GB0100110D0 - Modulation of calcium channel activity - Google Patents
Modulation of calcium channel activityInfo
- Publication number
- GB0100110D0 GB0100110D0 GBGB0100110.6A GB0100110A GB0100110D0 GB 0100110 D0 GB0100110 D0 GB 0100110D0 GB 0100110 A GB0100110 A GB 0100110A GB 0100110 D0 GB0100110 D0 GB 0100110D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- modulation
- calcium channel
- channel activity
- activity
- calcium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000312 Calcium Channels Proteins 0.000 title 1
- 102000003922 Calcium Channels Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0100110.6A GB0100110D0 (en) | 2001-01-04 | 2001-01-04 | Modulation of calcium channel activity |
PCT/GB2002/000013 WO2002059155A2 (en) | 2001-01-04 | 2002-01-03 | Modulation of calcium channel activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0100110.6A GB0100110D0 (en) | 2001-01-04 | 2001-01-04 | Modulation of calcium channel activity |
Publications (1)
Publication Number | Publication Date |
---|---|
GB0100110D0 true GB0100110D0 (en) | 2001-02-14 |
Family
ID=9906193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB0100110.6A Ceased GB0100110D0 (en) | 2001-01-04 | 2001-01-04 | Modulation of calcium channel activity |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB0100110D0 (en) |
WO (1) | WO2002059155A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR038536A1 (en) | 2002-02-25 | 2005-01-19 | Upjohn Co | N-ARIL-2-OXAZOLIDINONA-5- CARBOXAMIDS AND ITS DERIVATIVES |
US7141588B2 (en) | 2002-02-25 | 2006-11-28 | Pfizer, Inc. | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
US7304050B2 (en) | 2003-09-16 | 2007-12-04 | Pfizer Inc. | Antibacterial agents |
JP2008526905A (en) | 2005-01-12 | 2008-07-24 | サノフィ−アベンティス | Use of TRPC channels to treat cardiovascular disease |
PL1954718T3 (en) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
JP5486808B2 (en) | 2005-11-30 | 2014-05-07 | アッヴィ・インコーポレイテッド | Monoclonal antibody against amyloid beta protein and use thereof |
JO3598B1 (en) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | Boronic acids and esters as inhibitors of fatty acid amide hydrolase |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
WO2009126691A1 (en) | 2008-04-09 | 2009-10-15 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
WO2010124113A1 (en) | 2009-04-23 | 2010-10-28 | Infinity Pharmaceuticals, Inc. | Anti-fatty acid amide hydrolase-2 antibodies and uses thereof |
US8765735B2 (en) | 2009-05-18 | 2014-07-01 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US8927551B2 (en) | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
US9149465B2 (en) | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
WO2011097233A1 (en) | 2010-02-03 | 2011-08-11 | Infinity Pharmaceuticals, Inc. | Fatty acid amide hydrolase inhibitors |
CN104744591B (en) | 2010-04-15 | 2022-09-27 | Abbvie德国有限责任两合公司 | Amyloid beta binding proteins |
CN105348387B (en) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | Amyloid beta binding proteins |
-
2001
- 2001-01-04 GB GBGB0100110.6A patent/GB0100110D0/en not_active Ceased
-
2002
- 2002-01-03 WO PCT/GB2002/000013 patent/WO2002059155A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2002059155A3 (en) | 2002-12-05 |
WO2002059155A2 (en) | 2002-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2383706B (en) | Modulation control | |
GB0100110D0 (en) | Modulation of calcium channel activity | |
HK1067907A1 (en) | Amplifier modulation | |
AU2002366103A8 (en) | Modulators of rho c activity | |
AU2002364125A8 (en) | Antisense modulation of mdm2 expression | |
GB0122914D0 (en) | Modulation of stat activity | |
HK1049618A1 (en) | Modulation of bone formation | |
AU2002366788A8 (en) | Antisense modulation of ship-1 expression | |
IL156804A0 (en) | Modulation of gsk-3beta activity and its different uses | |
GB0126781D0 (en) | Modulation | |
AU2002357102A8 (en) | Antisense modulation of cd36l1 expression | |
GB0124321D0 (en) | Modulation determination | |
AU2003257966A8 (en) | Antisense modulation of lar expression | |
IL162747A0 (en) | Modulation of heat-shock-protein-based immunotherapies | |
AU2003297897A8 (en) | Modulation of stat 6 expression | |
AU2003295790A8 (en) | Modulation of iap-like expression | |
AU2003299204A8 (en) | Focal calcium channel modulation | |
AU2002217314A1 (en) | Modulation of calcium channel activity | |
AU2002359428A8 (en) | Modulators of rho c activity | |
AU2003271988A8 (en) | Modulation of tgfbeta-like signalling pathways | |
AU2003243589A8 (en) | Antisense modulation of smrt expression | |
AU2002357101A8 (en) | Antisense modulation of cd81 expression | |
IL158413A0 (en) | Treatment of adhd | |
GB0026727D0 (en) | Modulation of PDEII activity | |
AU2002329838A1 (en) | Modulation of appl expression |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |